ALBPS.PA Biophytis S.A. EURONEXT +17.65% to €0.03 24 Mar 2026: catalysts in focus

Biophytis S.A. (ALBPS.PA) on EURONEXT jumped 17.65% intraday to €0.03 on 24 Mar 2026, driven by heavy intraday volume of 1,438,765 shares. The move follows low trading levels against a 50-day average price of €0.05 and a 200-day average of €0.11, keeping the stock volatile. We review why the ALBPS.PA stock is moving today, how fundamentals and technicals align, and what the Meyka AI forecast and grade say about upside and risk for Europe-listed small-cap biotech investors.

Intraday move and drivers for ALBPS.PA stock

ALBPS.PA stock rose 17.65% to €0.03 on EURONEXT intraday trading 24 Mar 2026, with a session low of €0.0279 and high of €0.03. Volume reached 1,438,765 versus an average volume of 1,747,571, signalling above-average attention. The stock opened at €0.0285 after a previous close of €0.0255. Market participants cited renewed interest in Biophytis’s clinical-stage pipeline as the likely near-term catalyst.

Fundamentals and valuation for ALBPS.PA stock

Biophytis S.A. is a clinical-stage biotechnology company focused on Sarconeos (BIO101) and Macuneos (BIO201). The company shows an EPS of -0.34 and a PE of -0.08, reflecting negative earnings. Market capitalization is approximately €648,138.00, with 23,230,769 shares outstanding. Cash per share is €0.06 and book value per share is negative. Compared with the broader Healthcare sector (avg PE ~29.19), ALBPS.PA’s valuation is distressed, typical for small clinical biotechs with limited commercial revenue.

Technical indicators and trading setup for ALBPS.PA stock

Technically the stock looks oversold: RSI 25.83 and MFI 15.25 indicate buying interest could emerge on rebounds. The 50-day average price is €0.05 and the 200-day average is €0.11, both above the current price, forming resistance. ADX at 37.67 signals a strong trend. Bollinger Bands show a tight range (upper €0.06, middle €0.04, lower €0.02), so intraday breakouts can be volatile. Traders should watch order book liquidity due to low market cap.

Catalysts, news and clinical outlook for ALBPS.PA stock

Key value drivers remain clinical readouts and regulatory updates for Sarconeos (BIO101) and Macuneos (BIO201). The company’s next public earnings announcement is scheduled for 11 Sep 2026. Biophytis partners with AFM-Telethon on the DMD program, which can influence sentiment around trial milestones. Public newsflow has been light; sector developments sometimes move small-cap peers, as seen in recent biotech coverage source.

Meyka grade and price forecast for ALBPS.PA stock

Meyka AI rates ALBPS.PA with a score out of 100: 71.08, Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of €2.98 and a three-year price of €1.25. Versus the current €0.03, the yearly projection implies an upside of roughly +9,833.33% and the three-year implies about +4,066.67%. Forecasts are model-based projections and not guarantees.

Risks and trading considerations for ALBPS.PA stock

ALBPS.PA is a high-risk, high-volatility micro-cap biotech. Market cap is €648,138.00, liquidity is thin despite intraday volume spikes, and the current ratio is 0.35, indicating short-term coverage risk. Enterprise value is elevated relative to reported cash. Clinical trial outcomes, regulatory delays, or equity dilution present material downside. Given negative free cash flow and mixed balance-sheet metrics, position sizing and stop-loss discipline are essential for traders.

Final Thoughts

ALBPS.PA stock’s intraday jump to €0.03 on 24 Mar 2026 highlights the volatility and event-driven nature of small-cap biotech trading on EURONEXT. Technicals show oversold indicators and tight intraday bands, which can produce sharp bounces. Fundamentals remain fragile: EPS -0.34, market cap €648,138.00, and a low current ratio. Meyka AI’s proprietary grade (B+, score 71.08) weighs both sector context and growth signals while flagging material balance-sheet risk. Meyka AI’s forecast model projects €2.98 at one year and €1.25 at three years; these imply very large percentage upside versus today but come with high model uncertainty. Forecasts are model-based projections and not guarantees. For traders we recommend monitoring clinical news, volume confirmation, and tight risk controls. For a live quote and deeper metrics see our coverage on Meyka’s stock page: Meyka ALBPS.PA page. Meyka AI provides this as an AI-powered market analysis platform, not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.